DIAGNOSIS OF CHRONIC MYELOMONOCYTIC LEUKEMIA
Keywords:
chronic myelomonocytic leukemia, diagnostic, WHO classification.Abstract
Summary. The available literature data and the results
of authors’ own studies on the clinical and laboratory
features of chronic myelomonocytic leukemia (CMML)
are presented. CMML is a myelodysplastic/myeloproliferative neoplasm with monocyte count of at least
1.0•109
/l, without BCR-ABL1 fusion gene and with
fewer than 20% blasts and promonocytes in bone marrow and peripheral blood. Diagnostic criteria of CMML
as well as morphocytochemical, immunophenotypic
and cytogenetic characteristics of CMML according to
2017 revision of WHO classification are reviewed. The
data on 524 CMML patients diagnosed at the Oncohematology Department of R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology in
1996–2016 are summarized.
References
Maynadié M, Verret C, Moskovtchenko P, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996; 74 (2): 288–90.
Gologan R, Georgescu D, Tatic A, et al. Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania. Leuk Res 2009; 33 (11): 1556–61.
Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Jaffe ES, Harris NL, Stein H, Vardiman YW (eds). Lyon: IARC Press, 2001. 351 p.
Arber DA, Ozazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms. Blood 2016; 127 (20): 2391–405.
Takahashi K, Pemmaraju N, Strati P, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 2013; 122 (16): 2807–11; quiz 2920.
Myelodysplastic/myeloproliferative neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed, Vol 2. Lyon: IARC Press, 2017: 81–96.
Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008; 112 (1): 45–52.
Dinmohamed AG, Brink M, Visser O, et al. Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012. Br J Haematol 2015; 171 (3): 436–9.
Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 2014; 165 (3): 273–86.
Bain BJ. Leukaemia diagnosis, 5th ed. Hoboken, NJ: John Wiley & Sons, Inc., 2017. 576 p.
Gluzman DF, Sklyarenko LM, Telegeev GD, et al. Diagnosis of myeloid neoplasms and acute leukemias. Scientific and methodical guide. Kyiv: DIA, 2016. 124 p. (in Ukrainian).
Lacronique-Gazaille C, Chaury MP, Le Guyader A, et al. A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 2007; 92 (6): 859–60.
Bacher U, Haferlach T, Schnittger S, et al. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011; 153 (2): 149–67.
Sojitra P, Gandhi P, Fitting P, et al. Chronic myelomonocytic leukemia monocytes uniformly display a population of monocytes with CD11c underexpression. Am J Clin Pathol 2013; 140 (5): 686–92.
Xu Y, McKenna RW, Karandikar NJ, et al. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 2005; 124 (5): 799–806.
Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 2015; 125 (23): 3618–26.
Ji P, Peterson LC. Plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Blood 2014; 123 (21): 3220.
Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol 2014; 89 (12): 1111–5.
Patnaik MM, Wassie EA, Lasho TL, et al. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol 2015; 90 (5): 411–6.
Malcovati L, Rumi E, Cazzola M. Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Haematologica 2014; 99 (11): 1650–2.
Germing U, Strupp C, Aivado M, Gattermann N. New prognostic parameters for chronic myelomonocytic leukemia. Blood 2002; 100 (2): 731–2; author reply 732–3.
Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003; 101 (9): 3386–90.
Breccia M, Latagliata R, Mengarelli A, et al. Prognostic factors in myelodysplastic and myeloproliferative types of chronic
myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. Haematologica 2004; 89 (7): 866–8.
Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31 (19): 2428–36.
Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia:
a retrospective analysis of 213 patients. Blood 2002; 99 (3): 840–9.
